Fibrocell to Present at Canaccord Genuity 37th Annual Growth Conference
August 03 2017 - 8:00AM
Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company
focused on transformational autologous cell-based therapies for
skin and connective tissue diseases, today announced that John
Maslowski, President and Chief Executive Officer, will present at
the Canaccord Genuity 37th Annual Growth Conference on Thursday,
August 10 at 2:30 pm EDT in Boston, Massachusetts.
A live webcast of Fibrocell’s presentation will
be available under the investor relations section of the Company’s
website at www.fibrocell.com/investors/events and archived for 30
days. Please visit Fibrocell’s website several minutes prior
to the start of the broadcast to ensure adequate time for any
software download that may be necessary.
About Fibrocell
Fibrocell is an autologous cell and gene therapy
company translating personalized biologics into medical
breakthroughs for diseases affecting the skin and connective
tissue. Fibrocell’s most advanced product candidate, FCX-007,
is the subject of a Phase 1/2 clinical trial for the treatment of
recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in
pre-clinical development of FCX-013, its product candidate for the
treatment of moderate to severe localized scleroderma.
Fibrocell’s gene therapy portfolio is being developed in
collaboration with Intrexon Corporation (NYSE: XON), a leader in
synthetic biology. For more information, visit
http://www.fibrocell.com or follow Fibrocell on Twitter at
@Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo and Fibrocell
Science are trademarks of Fibrocell Science, Inc. and/or its
affiliates. All other names may be trademarks of their
respective owners.
Investor & Media Relations Contact:
Karen Casey
484.713.6133
kcasey@fibrocell.com
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Jul 2023 to Jul 2024